Exchange: NASDAQ·Updated 07:30 PM EST

ACAD News

News
all
press releases
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
Capricor and Savara face Nov.22 FDA deadlines, while Beren Therapeutics awaits a Tuesday decision on Adrabetadex.
Stocktwits
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
Capricor and Savara face Nov.22 FDA deadlines, while Beren Therapeutics awaits a Tuesday decision on Adrabetadex.
Stocktwits
More News
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delawares May 2025 decision upholding Acadias U.S. Patent No. 11,452,721 (the 721 patent...
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's...
Business Wire
Acadia (ACAD) delivered earnings and revenue surprises of +63.16% and +2.22%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID, said Catherine Owen Adams...
Business Wire
VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.
Zacks
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +8.33% and +69.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026...
PR Newswire
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. Greenwich Mean Time.A live webcast of Acadias fireside chat will be accessible on the companys website...
Business Wire

Advertisement|Remove ads.